Extended anticoagulation with low-dose rivaroxaban (Xarelto, Bayer/Janssen) after hospitalization for COVID-19 may reduce the risk of venous thromboembolism (VTE) without worsening the risk of bleeding in patients who had been considered high-risk for VTE, a multicenter randomized trial suggests. The primary efficacy outcome occurred in five (3%) patients assigned to rivaroxaban and 15 (9%) […]
Extended anticoagulation with low-dose rivaroxaban (Xarelto, Bayer/Janssen) after hospitalization for COVID-19 may reduce the risk of venous thromboembolism (VTE) without worsening the risk of bleeding in patients who had been considered high-risk for VTE, a multicenter randomized trial suggests. The primary efficacy outcome occurred in five (3%) patients assigned to rivaroxaban and 15 (9%) […]
In stable patients hospitalized with COVID-19 and elevated D-dimer levels, therapeutic anticoagulation with rivaroxaban 20 mg once daily did not improve clinical outcomes but did increase bleeding compared with in-hospital prophylactic anticoagulation in the ACTION trial. The trial also intended to test a therapeutic regimen of enoxaparin (1 mg/kg twice daily) in unstable patients but did […]
